As of mid-2026, Kintor reports that the pivotal Phase III stage in China met its primary endpoint with statistically significant and clinically meaningful efficacy in male AGA; a 52-week long-term safety Phase III also met endpoint. US Phase II positive. NDA planned in China.
In the full monograph
- What it is, and how it works
- What the evidence shows — randomized trials, observational data, animal studies, graded and cited
- Dose, form, and timing
- What to expect, and how soon
- Who should be careful, and what to check first
- The verdict
MEMBERS
Read the full monograph
Members get every monograph in the library, the research assistant, and the stack tracker — with a 30-day money-back guarantee. Not ready? Start free with the Proven Supplements Starter Guide.